Potential antitumour activity of pasireotide on pituitary tumours in acromegaly

Eva C. Coopmans; Aart J. van der Lely; Joppe J. Schneiders; Sebastian J.C.M.M. Neggers

doi:10.1016/S2213-8587(19)30113-5

Potential antitumour activity of pasireotide on pituitary tumours in acromegaly

Eva C. Coopmans, Aart J. van der Lely, Joppe J. Schneiders, Sebastian J.C.M.M. Neggers

Research output: Contribution to journal › Letter › peer-review

21 Citations (Scopus)

Original language	English
Pages (from-to)	425-426
Number of pages	2
Journal	The Lancet Diabetes and Endocrinology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1016/S2213-8587(19)30113-5
Publication status	Published - Jun 2019
Externally published	Yes

Access to Document

10.1016/S2213-8587(19)30113-5

Cite this

@article{52420f5296f9441d849379fc0ad4305f,

title = "Potential antitumour activity of pasireotide on pituitary tumours in acromegaly",

author = "Coopmans, {Eva C.} and {van der Lely}, {Aart J.} and Schneiders, {Joppe J.} and Neggers, {Sebastian J.C.M.M.}",

note = "Funding Information: AJvdL is a consultant for Pfizer, and has received speaker fees from Novartis, Ipsen, and Pfizer. SJCMMN has received research grants and speaker fees from Ipsen, Novartis, and Pfizer, and consulting fees from Ipsen. ECC and JJS have nothing to disclose. ",

year = "2019",

month = jun,

doi = "10.1016/S2213-8587(19)30113-5",

language = "English",

volume = "7",

pages = "425--426",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Potential antitumour activity of pasireotide on pituitary tumours in acromegaly

AU - Coopmans, Eva C.

AU - van der Lely, Aart J.

AU - Schneiders, Joppe J.

AU - Neggers, Sebastian J.C.M.M.

N1 - Funding Information: AJvdL is a consultant for Pfizer, and has received speaker fees from Novartis, Ipsen, and Pfizer. SJCMMN has received research grants and speaker fees from Ipsen, Novartis, and Pfizer, and consulting fees from Ipsen. ECC and JJS have nothing to disclose.

PY - 2019/6

Y1 - 2019/6

UR - http://www.scopus.com/inward/record.url?scp=85065622124&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(19)30113-5

DO - 10.1016/S2213-8587(19)30113-5

M3 - Letter

C2 - 30956093

AN - SCOPUS:85065622124

SN - 2213-8587

VL - 7

SP - 425

EP - 426

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 6

ER -